Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2025-10-14 00:00:00 ET · period of report 2025-10-10 · accession 0001104659-25-099252 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-10-14 | 2025-10-10 | PTGX | Waddill William D. | Dir | S - Sale+OE | $81.62 | -12.0K | 13.1K | -48% | -$979.5K |
| D | 2025-10-14 | 2025-10-10 | PTGX | Waddill William D. | Dir | M - OptEx | $6.98 | +12.0K | 17.1K | +234% | +$83.8K |
| D | 2025-10-14 | 2025-10-10 | PTGX | Waddill William D. | Dir | M - OptEx | $0.00 | -12.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-10 | S | D | 8,000 | $87.81 | 5,130 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $86.71 to $88.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2025-10-10 | M | A | 12,000 | $6.98 | 17,130 | D | — | — | |
| 3 | Common | Common Stock | 2025-10-10 | S | D | 4,000 | $69.25 | 13,130 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2025-10-10 | M | D | 12,000 | $0.00 | 0 | D | $6.98 · — to 2028-05-28 | 12,000 Common Stock | (F3) These stock options are fully vested. |